23,590 Shares in Enovis Corporation $ENOV Acquired by Caprock Group LLC

Caprock Group LLC acquired a new position in shares of Enovis Corporation (NYSE:ENOV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 23,590 shares of the company’s stock, valued at approximately $729,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in Enovis by 0.4% during the 3rd quarter. Rhumbline Advisers now owns 173,023 shares of the company’s stock worth $5,250,000 after acquiring an additional 682 shares during the period. Impax Asset Management Group plc grew its position in Enovis by 47.5% in the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock valued at $9,425,000 after buying an additional 100,000 shares during the last quarter. Bryce Point Capital LLC acquired a new position in Enovis in the 3rd quarter valued at $549,000. Homestead Advisers Corp raised its position in Enovis by 8.6% during the 3rd quarter. Homestead Advisers Corp now owns 84,176 shares of the company’s stock worth $2,554,000 after buying an additional 6,700 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new stake in shares of Enovis in the 3rd quarter worth $430,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling

In other Enovis news, insider John Kleckner bought 2,468 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were bought at an average cost of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ENOV. Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Evercore restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. BTIG Research assumed coverage on Enovis in a report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective for the company. UBS Group reiterated a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Finally, Canaccord Genuity Group dropped their price target on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $21.77 on Tuesday. The business’s 50-day simple moving average is $24.99 and its 200 day simple moving average is $28.46. The company has a market cap of $1.24 billion, a P/E ratio of -0.92 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. Enovis Corporation has a one year low of $21.00 and a one year high of $44.76.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.